Evaluation of Androgen Receptor in Relation to Estrogen Receptor (AR/ER) and Progesterone Receptor (AR/PgR): A New Must in Breast Cancer?

Table 3

Impact of AR/ER and AR/PgR ratios on OS in patients with AR and ER detected both in primary tumor and metastasis (no. 24).

OS (HR) according to best cut-off of the ratios
		Primary tumor	Metastasis
AR/ER; (cut-off 0.90)		0.33; (95% CI: 0.08 – 1.36); p = 0.127	0.09; (95% CI: 0.01 - 0.70); p = 0.022
AR/PgR; (cut-off 0.96)		2.56; (95% CI: 0.56 – 11.72); p = 0.224	0.53; (95% CI: 0.18 – 1.59); p = 0.259
Median OS (months) according to AR/ER difference between primary tumor and metastasis
		Metastasis
		<0.90	≥0.90
Primary tumor	<0.90	32.4; (95% CI: 23.9 - NR)	36.4; (NR)	p=0.011
	≥0.90	42.2; (95% CI: 14.5 - 87.7)	92.0; (95% CI: 89.4 - NR)

AR, androgen receptor; ER, estrogen receptor; PgR, progesterone receptor; OS, overall survival; HR, hazard ratio (AR/ER and AR/PgR ratios <cut-off are the reference category); CI, confidence interval; ND, not determinable; NR, not reached.